Vanda Pharmaceuticals has expressed concern over the FDA's recent guidance on communication about unapproved uses of approved drugs. The guidance could lead to criminal misbranding liability for drugmakers sharing new clinical trial results unless they meet the FDA's vague standards. Vanda views this as a threat to free speech and due process, and an overreach without clear congressional direction, potentially impacting medical practice and public health.